{"id":34651,"date":"2025-06-03T21:57:48","date_gmt":"2025-06-03T13:57:48","guid":{"rendered":"https:\/\/flcube.com\/?p=34651"},"modified":"2025-06-03T21:57:49","modified_gmt":"2025-06-03T13:57:49","slug":"zelgen-biopharmaceuticals-presents-clinical-updates-for-alveltamig-nilvanstomig-and-zggs15-at-asco-2025","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=34651","title":{"rendered":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025"},"content":{"rendered":"\n<p>China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688266:SHA\">SHA: 688266<\/a>) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.<\/p>\n\n\n\n<p><strong>Alveltamig (ZG006) Clinical Results<\/strong><br>Alveltamig, a trispecific antibody targeting two epitopes of DLL3 and CD3, showed impressive results in the Phase II dosage optimization study for refractory advanced small cell lung cancer (SCLC). Objective response rates (ORRs) were 62.5% (10mg) and 58.3% (30mg), with disease control rates (DCRs) of 70.8% (10mg) and 66.7% (30mg). Additional studies (ZG006-001 and ZG006-003) further confirmed its anti-tumor activity and tolerability.<\/p>\n\n\n\n<p><strong>Nilvanstomig (ZG005) Clinical Results<\/strong><br>Nilvanstomig, an anti PD-1\/TIGIT bispecific antibody, demonstrated significant efficacy in cervical cancer patients. In the ZG005-001 study, the 20mg\/kg group showed a confirmed ORR of 40.9% and DCR of 68.2%. Combination therapies in ZG005-003 and ZG005-004 studies also yielded high ORRs and DCRs, highlighting its potential in advanced cervical and neuroendocrine cancers.<\/p>\n\n\n\n<p><strong>ZGGS15 Clinical Results<\/strong><br>ZGGS15, a bispecific antibody targeting LAG-3 and TIGIT, showed a disease control rate (DCR) of 35.3% in the ZGGS15-001 study, with 62.5% of lung adenocarcinoma patients achieving stable disease (SD). The drug was well-tolerated with no dose-limiting toxicity (DLT) observed.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688266_20250603_1KY9.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 688266_20250603_1KY9.\"><\/object><a id=\"wp-block-file--media-9be64322-3c94-492c-b91f-888b08371c12\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688266_20250603_1KY9.pdf\">688266_20250603_1KY9<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/688266_20250603_1KY9.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-9be64322-3c94-492c-b91f-888b08371c12\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs&#8230;<\/p>\n","protected":false},"author":1,"featured_media":34653,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,17,28,905,246],"class_list":["post-34651","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-academic-conference","tag-clinical-trial-results","tag-multi-specific-antibodies","tag-sha-688266","tag-zelgen-biopharmaceuticals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=34651\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025\" \/>\n<meta property=\"og:description\" content=\"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=34651\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-03T13:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-03T13:57:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"912\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025\",\"datePublished\":\"2025-06-03T13:57:48+00:00\",\"dateModified\":\"2025-06-03T13:57:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651\"},\"wordCount\":229,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0304-1.webp\",\"keywords\":[\"Academic conference\",\"Clinical trial results\",\"Multi-specific antibodies\",\"SHA: 688266\",\"Zelgen Biopharmaceuticals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34651#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=34651\",\"name\":\"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0304-1.webp\",\"datePublished\":\"2025-06-03T13:57:48+00:00\",\"dateModified\":\"2025-06-03T13:57:49+00:00\",\"description\":\"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=34651\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0304-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/06\\\/0304-1.webp\",\"width\":912,\"height\":608,\"caption\":\"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=34651#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry","description":"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=34651","og_locale":"en_US","og_type":"article","og_title":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025","og_description":"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.","og_url":"https:\/\/flcube.com\/?p=34651","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-06-03T13:57:48+00:00","article_modified_time":"2025-06-03T13:57:49+00:00","og_image":[{"width":912,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=34651#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=34651"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025","datePublished":"2025-06-03T13:57:48+00:00","dateModified":"2025-06-03T13:57:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=34651"},"wordCount":229,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=34651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","keywords":["Academic conference","Clinical trial results","Multi-specific antibodies","SHA: 688266","Zelgen Biopharmaceuticals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=34651#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=34651","url":"https:\/\/flcube.com\/?p=34651","name":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025 - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=34651#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=34651#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","datePublished":"2025-06-03T13:57:48+00:00","dateModified":"2025-06-03T13:57:49+00:00","description":"China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) presented clinical updates for its investigational drugs alveltamig (ZG006), nilvanstomig (ZG005), and ZGGS15 at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The data highlighted the promising efficacy and safety profiles of these drugs across multiple cancer types.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=34651#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=34651"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=34651#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","width":912,"height":608,"caption":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=34651#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Zelgen Biopharmaceuticals Presents Clinical Updates for Alveltamig, Nilvanstomig and ZGGS15 at ASCO 2025"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/06\/0304-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34651","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=34651"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34651\/revisions"}],"predecessor-version":[{"id":34654,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/34651\/revisions\/34654"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/34653"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=34651"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=34651"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=34651"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}